ITGAX and neoplasm: Compared with the diluent-treated control group, the CCL19-treated CC-10 TAg mice showed significant increases in the frequency of CD4 (20%), CD8 (50%) and CD11c+DEC205+ DC (70%) and a decrease in CD4+CD25+ Treg (20%) cells at the tumour site (Table 1).